Market Overview

Catalyst Alert: Amgen/Regeneron Patent Case Appeal Could Be Decided By April

Share:
Catalyst Alert: Amgen/Regeneron Patent Case Appeal Could Be Decided By April
Related REGN
The Daily Biotech Pulse: EyePoint Licenses Eye Inflammation Drug, Insys Strategic Review Of Opioid Assets, Neos Offering
Earnings Scheduled For November 6, 2018
Total Pharma Tracker's Daily BioPharma Focus: Ziopharm Has Excellent Products, But Not Much Cash (Seeking Alpha)
Related SNY
The Daily Biotech Pulse: Denali's Positive Results, Novartis' Substance Abuse Therapy Launch, Medtronic Earnings
The Daily Biotech Pulse: EyePoint Licenses Eye Inflammation Drug, Insys Strategic Review Of Opioid Assets, Neos Offering

After the close on Monday, Amgen, Inc. (NASDAQ: AMGN) announced that the U.S. District Court of Delaware had denied the motion by Sanofi SA (ADR) (NYSE: SNY) and Regeneron Pharmaceuticals Inc (NASDAQ: REGN) to stay the injunction pending the appeal of the ongoing PCSK9 litigation in the Court of Appeals for the Federal Circuit.

Chardan Capital’s Gbola Amusa maintains a Neutral rating on the company, with a price target of $345.

District Court Ruling

In its ruling, the District Court extended the timing of the injunction from 30 days to 45 days, “allowing Sanofi and Regeneron to seek review of the Court's injunction and stay denial at the CAFC,” the analyst mentioned.

Amusa believes that denying the stay could lead to the appeal process being accelerated, as well as the earlier-than-expected potential removal of Regeneron’s Praluent from the U.S. market.

Final Decision in April

“In light of yesterday's block of the injunction stay and after our further consultation with expert legal counsel, we now believe that the appeals process is likely to be substantially accelerated, with a potential final decision from the CAFC as early as April 2017,” the analyst explained.

Given expectation of the potential loss of Praluent from the U.S. market in the near future, as well as the cardiovascular outcomes data for Repatha, to be announced at the American College of Cardiology Conference on March 17–19, potentially de-risking the PCSK9 inhibitor class, Amusa recommends Amgen over Regeneron Pharma for those wanting to invest in the PCSK9 inhibitor space.

Image Credit: Public Domain, via Wikimedia Commons

Latest Ratings for REGN

DateFirmActionFromTo
Oct 2018Morgan StanleyMaintainsEqual-WeightEqual-Weight
Oct 2018Canaccord GenuityMaintainsHoldHold
Oct 2018Cantor FitzgeraldInitiates Coverage OnNeutral

View More Analyst Ratings for REGN
View the Latest Analyst Ratings

Posted-In: Analyst Color Biotech News Hedge Funds Reiteration Legal Analyst Ratings Movers Best of Benzinga

 

Related Articles (AMGN + REGN)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
SCCOBradescoUpgrades42.0
PFODFJefferiesUpgrades0.0
TEDUJefferiesDowngrades5.8
INVVYJefferiesDowngrades0.0
UMPQPiperJaffrayUpgrades20.0
View the Latest Analytics Ratings
Don't Miss Out!
Join Our Newsletter
Subscribe to:
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
Your weekly roundup of hot topics in the exciting world of fintech.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

The Market In 5 Minutes: Altaba, American Apparel And Alabama-Clemson

10 Most Popular TV Series In The U.S.: None Are Recent Award Winners